Brachyury: Strategies for Drugging an Intractable Cancer Therapeutic Target
Helena Robinson1, Ramsay J McFarlane1, Jane A Wakeman1
1North West Cancer Research Institute, School of Medical Sciences, Bangor University, Deiniol Road, Bangor, Gwynedd LL57 2UW, UK.
Abstract:
New approaches to drug discovery are unlocking enormous therapeutic potential residing in cancer-specific molecules. Brachyury is emerging as an exciting new drug target for the rare bone cancer chordoma. Here, recent advances targeting Brachyury in chordoma are discussed and how these might open doors to the targeting of other, more common cancer types.
Insights
New drug discovery approaches target cancer molecules. Brachyury is a promising target for chordoma, a rare bone cancer, with potential applications in other cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Cancer-specific molecules offer significant therapeutic potential.
- Brachyury is identified as a key target in rare bone cancer, chordoma.
Purpose of the Study:
- To review recent advancements in targeting Brachyury for chordoma treatment.
- To explore the broader implications of Brachyury targeting for other cancer types.
Main Methods:
- Literature review of recent studies on Brachyury and chordoma.
- Analysis of emerging therapeutic strategies targeting the Brachyury protein.
Main Results:
- Brachyury is a validated target in chordoma, with ongoing drug development.
- Targeting Brachyury shows promise beyond chordoma, potentially applicable to other malignancies.
Conclusions:
- Targeting Brachyury represents a novel therapeutic strategy for chordoma.
- Advances in Brachyury-targeted therapies may extend to more prevalent cancer types, broadening treatment options.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:38Mitogens and the Cell Cycle